Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Wesfarmers (ASX:WES) ups bid for Australian Pharmaceutical (ASX:API)

The Wesfarmers Ltd (ASX: WES) share price will be on watch today after the business increased its takeover offer to $1.55 per share for Australian Pharmaceutical Industries Ltd (ASX: API). 

The Wesfarmers Ltd (ASX: WES) share price will be on watch today after the business increased its takeover offer to $1.55 per share for Australian Pharmaceutical Industries Ltd (ASX: API).

The API board is set to unanimously recommend the revised offer subject to no superior offers to land on the table and an independent expert valuation.

API is best known for its Priceline store network and distribution of essential medicines.

What was announced?

Wesfarmers has come to the table with a $1.55 per share offer for API, valuing the business at $770 million.

The revised offer is a 37% premium to the last trading price before the first proposal was announced.

The API board previously rejected Wesfarmers’s initial $1.38 per share cash offer in July. The board cited that the proposal did not reflect the underlying value and growth prospects of the business.

This time, the board is set to recommend the offer and allow Wesfarmers to comb over the books.

Additionally, major shareholder Washington H. Soul Pattinson and Co. Ltd (ASX: SOL) who owns 19.3% of API is set to vote in favour of the offer.

The offer is still subject to a number of conditions being met including:

  • Satisfactory due diligence by Wesfarmers
  • No superior proposal being received
  • Clearance by the Australian Competition and Consumer Commission (ACCC)
  • Unanimous board recommendation
  • A binding offer by Wesfarmers

Why is Wesfarmers acquiring API?

Wesfarmers is looking to expand its activities into the pharmacy store and distribution network.

The business will be able to leverage its extensive supply chains, product range and online capabilities to enhance API’s value proposition.

Wesfarmers Managing Director Rob Scott said:

““Wesfarmers supports the community pharmacy model, including the pharmacy ownership and location rules… API would also provide the basis of a new Healthcare division of Wesfarmers and a platform from which to invest and develop capabilities in the growing health, wellbeing and beauty sector.”

What does this mean for shareholders?

Nothing for now. The proposal is still subject to a number of conditions.

If the deal goes through, API shareholders will receive $1.55 per share minus any distributions made.

No action is required by Wesfarmers shareholders, as API will be consumed into the broader Wesfarmers group.

To keep up to date on all the latest news regarding Wesfarmers and the ASX, be sure to bookmark the Rask Media home page.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Lachlan does not have a financial or commercial interest in any of the companies or funds mentioned.
Skip to content